How to Inject Tesofensine Subq — Protocol & Technique

Research from peptide stability studies shows that subcutaneous injection technique affects tesofensine absorption by 20–35%. Making the difference between therapeutic plasma levels and subtherapeutic dosing. The compound's lipophilicity means it requires precise placement in adipose tissue, not muscle, to achieve the extended release profile that makes once-daily dosing effective. Get the angle wrong, inject too deep, or fail to rotate sites properly, and you're introducing variables that clinical dosing protocols can't account for.

We've worked with researchers using tesofensine in metabolic studies for years. The gap between doing it right and doing it wrong isn't the injection itself. It's the preparation sequence most protocols gloss over.

How do you inject tesofensine subq correctly?

To inject tesofensine subq, pinch a fold of subcutaneous fat at the injection site, insert a 27–30 gauge insulin syringe at a 45-degree angle into adipose tissue (5–7mm depth), inject slowly over 10–15 seconds, then withdraw and apply light pressure without rubbing. Proper site rotation. Abdominal quadrants, outer thigh, deltoid. Prevents lipohypertrophy and maintains consistent absorption across doses.

The distinction that matters: subcutaneous placement targets the layer between skin and muscle where vascular perfusion is slow enough to create sustained release. Intramuscular injection accelerates absorption, shortens half-life, and increases plasma concentration variability. Exactly what you don't want with a compound designed for steady-state norepinephrine and dopamine reuptake inhibition. This article covers how to inject tesofensine subq using proper reconstitution technique, site selection protocol, and injection angle that ensures adipose tissue placement every time.

Step 1: Reconstitute Lyophilised Tesofensine with Sterile Bacteriostatic Water

Lyophilised tesofensine arrives as a white powder in a sterile vial under vacuum seal. Reconstitution converts this into an injectable solution. But the sequence matters more than most protocols acknowledge. Use bacteriostatic water (0.9% benzyl alcohol), never sterile saline, because repeated needle punctures introduce contamination risk that benzyl alcohol suppresses for up to 28 days. Room temperature water (20–25°C) dissolves tesofensine faster than refrigerated water without compromising stability.

Withdraw the target volume of bacteriostatic water. Typically 2–3ml for a 5mg vial, giving you 2.5mg/ml or 1.67mg/ml concentration. Inject the water slowly down the inside wall of the vial, never directly onto the peptide powder. Direct impact causes foaming and protein denaturation. Let the vial sit undisturbed for 60–90 seconds. The powder will dissolve without agitation. Swirling is acceptable if dissolution is incomplete after two minutes, but never shake the vial. Shaking introduces microbubbles that denature the peptide structure irreversibly.

Store reconstituted tesofensine at 2–8°C (standard refrigerator temperature) and use within 28 days. Any temperature excursion above 8°C for more than 4 hours begins protein degradation that potency testing at home can't detect. Each 0.1ml drawn from a 2ml reconstituted vial at 2.5mg/ml concentration delivers 0.25mg tesofensine. Verify your math before drawing the first dose. We've seen researchers calculate backwards from total vial volume instead of concentration per ml, resulting in 3–4× overdosing. Concentration determines dose volume, not vial size.

Step 2: Prepare Injection Site and Sterilise the Target Zone

Subcutaneous fat depth varies by site. Abdominal tissue averages 15–25mm in most adults, outer thigh 10–18mm, deltoid 8–12mm. Select a site with sufficient adipose tissue that you can pinch a fold without pulling taut skin over muscle. The 'pinch test' is non-negotiable: if you can't gather 10mm of tissue between thumb and forefinger, the site lacks adequate subcutaneous depth and you risk intramuscular injection.

Rotate injection sites systematically to prevent lipohypertrophy (localised fat buildup) and lipoatrophy (fat loss). Both conditions impair absorption and create unpredictable pharmacokinetics. Divide the abdomen into four quadrants (left upper, left lower, right upper, right lower) and rotate through them on a 4–8 day cycle. Never inject within 5cm of the navel or any surgical scar. Scar tissue has reduced vascular perfusion that delays absorption by 30–50%.

Cleanse the site with 70% isopropyl alcohol using a circular motion from centre outward, covering a 5cm diameter area. Let the alcohol dry completely. Injecting through wet alcohol introduces it subcutaneously, causing stinging and tissue irritation. Drying takes 30–45 seconds. Don't blow on it, don't fan it, don't touch it. Just wait. Our team has learned this the hard way: every shortcut in the prep sequence shows up as injection-site reactions researchers incorrectly attribute to the peptide itself.

Step 3: Draw Tesofensine Dose Using Proper Syringe Technique to Avoid Contamination

Use a new insulin syringe (27–30 gauge, 0.5ml or 1ml barrel) for every injection. Never reuse syringes even for the same compound. Remove the vial cap and wipe the rubber stopper with a fresh alcohol prep pad. Let it dry 15 seconds. Draw air into the syringe equal to your target dose volume. This prevents vacuum formation inside the vial that makes subsequent draws progressively harder.

Insert the needle through the rubber stopper at a 90-degree angle, inject the air into the vial (not into the liquid. Aim for the headspace above the solution), then invert the vial so the needle tip is submerged. Draw slightly more than your target volume. If you need 0.2ml, draw 0.25ml. Hold the syringe at eye level, tap the barrel to consolidate air bubbles at the top, then push the plunger slowly to expel air and excess solution back into the vial until you reach exactly 0.2ml.

Double-check the dose volume before withdrawing the needle. The most common error we see in research settings isn't contamination. It's drawing 0.15ml when the protocol specifies 0.25ml because the researcher didn't account for dead space in the needle hub. Insulin syringes are calibrated to the plunger tip, but 0.03–0.05ml remains in the hub and needle after you stop pushing. For peptides where 0.1ml represents 0.25mg of active compound, a 0.05ml error is a 20% underdose.

Tesofensine Injection: Technique Comparison

Key Takeaways

• To inject tesofensine subq correctly, pinch subcutaneous fat, insert the needle at 45 degrees into adipose tissue 5–7mm deep, inject over 10–15 seconds, and rotate sites every 4–8 days to prevent lipohypertrophy.
• Reconstituted tesofensine stored at 2–8°C remains stable for 28 days. Any temperature excursion above 8°C for more than 4 hours begins irreversible protein denaturation.
• Subcutaneous injection into adipose tissue produces gradual absorption over 18–24 hours, maintaining steady-state plasma levels. Intramuscular injection accelerates absorption and shortens half-life by 40–60%.
• The abdominal region offers the most consistent subcutaneous fat depth (15–25mm average) and fastest absorption kinetics. Outer thigh and deltoid are acceptable secondary sites with proper pinch technique.
• Insulin syringes (27–30 gauge) minimise tissue trauma and injection-site reactions compared to larger-gauge needles. 0.5ml barrel size provides adequate volume for typical tesofensine doses of 0.1–0.3ml.
• Never inject within 5cm of the navel, surgical scars, or areas with visible veins. Reduced vascular perfusion at these sites delays absorption by 30–50% and creates unpredictable pharmacokinetics.

What If: Tesofensine Injection Scenarios

What If I Accidentally Inject Tesofensine Intramuscularly Instead of Subcutaneously?

You'll likely notice a sharper initial effect within 2–4 hours as the compound absorbs faster from muscle tissue. Followed by earlier offset than expected. Intramuscular injection isn't dangerous, but it defeats the extended-release design of subcutaneous protocols. Monitor for any unusual side effects (elevated heart rate, jitteriness, insomnia) that might indicate higher peak plasma concentration. Don't attempt to 'correct' it with an additional dose. Just resume proper subcutaneous technique at your next scheduled injection. The pharmacokinetic impact resolves within 24 hours.

What If the Injection Site Bleeds After I Withdraw the Needle?

Minor bleeding (a droplet or small streak) means you nicked a capillary. Completely normal and harmless. Apply light pressure with a clean gauze pad or alcohol wipe for 30–60 seconds. Don't rub or massage the site, as this can push the injected solution out of the subcutaneous space and into surrounding tissue. If bleeding continues beyond 2 minutes or forms a raised hematoma, you likely hit a larger vessel. Apply an ice pack for 10 minutes and avoid that exact spot for the next 7–10 days while it heals.

What If I Feel a Hard Lump at the Injection Site Hours After Injecting?

A firm subcutaneous nodule 4–12 hours post-injection usually indicates the solution pooled in one spot instead of dispersing through adipose tissue. Either because you injected too quickly (under 5 seconds) or the site has developing lipohypertrophy from repeated use. The lump will resolve on its own within 24–48 hours as the compound absorbs. Rotate to a different site for your next injection and slow your injection speed to 10–15 seconds. If lumps persist across multiple sites, consider switching to a lower concentration (dilute further with bacteriostatic water) to increase injection volume and improve dispersion.

What If the Reconstituted Solution Looks Cloudy or Has Floating Particles?

Discard the vial immediately. Cloudiness or visible particulates indicate bacterial contamination, protein aggregation, or incomplete dissolution. Properly reconstituted tesofensine is clear to slightly opalescent with no visible debris. Never inject a solution that looks abnormal. Contamination risks from multi-dose vials increase after 14 days even with bacteriostatic water, which is why 28-day stability is a maximum limit, not a target. If you're consistently seeing cloudiness within the first week, check your reconstitution technique. You may be injecting water directly onto the powder instead of down the vial wall, causing foaming and aggregation.

The Clinical Truth About Tesofensine Injection Technique

Here's the honest answer: most people who struggle with tesofensine protocols aren't failing because they can't handle the injection. They're failing because they're treating it like any other peptide. Tesofensine is lipophilic, meaning it has strong affinity for adipose tissue and relies on that environment for proper absorption kinetics. Inject it into muscle, and you get a pharmacokinetic profile that doesn't match any published dosing research. Inject it intradermally, and it pools at the injection site with minimal systemic absorption.

The other reality researchers need to hear: site rotation isn't optional. Injecting the same 2cm spot every day creates lipohypertrophy within 4–6 weeks. Localised fat accumulation that looks like a firm lump under the skin and reduces absorption by 30–40%. Once it develops, it takes 8–12 weeks to resolve even with complete site avoidance. We've worked with research teams who attributed poor tesofensine response to peptide quality when the actual problem was injection-site damage from inadequate rotation.

The technique itself. 45-degree angle, slow injection, proper pinch. Is straightforward. What separates successful protocols from failed ones is the discipline to execute every step the same way every time. Subcutaneous injection is a procedural skill, not an art form. Follow the sequence, rotate the sites, and the compound does what it's designed to do.

Proper injection technique is only half of a complete research peptide protocol. Our FAT Loss Stack combines synergistic compounds designed for subcutaneous administration with full reconstitution and dosing guidance. If you're exploring tesofensine as part of metabolic research, understanding how complementary peptides interact can deepen your experimental framework and improve reproducibility across trials.

Subcutaneous injection mastery for tesofensine isn't about perfect needle placement. It's about eliminating every variable that introduces dose-to-dose inconsistency. Get the reconstitution right, rotate your sites methodically, and inject at the correct angle into adipose tissue. That's the entire protocol. Everything else is just noise.